Cancer is the 2nd major cause of human morbidity and mortality. Thus, PhDs and MD/PhDs specifically trained in the discipline of Cancer Biology and professionally involved in cancer research and education are a critical national health need. It is our view that an interdisciplinary graduate curriculum with a major focus upon the biology of cancer that interfaces with clinicians engaged in cancer diagnosis and treatment provides an excellent means of training specialists with a sufficient breadth of perspective for successful independent careers in cancer research and education. This is an application for renewal of a training grant, currently in its 25th year, to support 6 pre-doctoral students principally from the Cancer Biology Graduate Program (CBGP) in the Department of Oncology at the Wayne State University (WSU) and the Barbara Ann Karmanos Cancer Institute (KCI). Trainees include both PhD and MD/PhD candidates and are selected from our diverse student population, including underrepresented minorities. Training draws from the outstanding clinical and research facilities at WSU/KCI and the expertise of 19 accomplished training faculty in areas ranging from neoplastic development, and invasion and metastasis, to cancer therapy, prevention, and cancer epidemiology. A cornerstone of our training environment is the CPGB, which provides a unique educational experience that integrates extended cancer courses, seminars by local and nationally/internationally recognized speakers, student-faculty research retreats, attendance at national/international meetings, and specialized workshops and courses, ultimately culminating in a PhD in Cancer Biology. Graduate students have the opportunity to become familiar with state-of-the- art concepts and methods in molecular and cell biology research, and with cutting-edge technologies through the KCI research cores, and receive clinical exposures to the cancer problem by """"""""rounding"""""""" with oncologists at the KCI Cancer Hospital. Specialized training in """"""""responsible conduct of research"""""""", grant writing, lab management, and career options are also provided. Training of our most outstanding graduate candidates from the CBGP is clearly enhanced by their competing for appointment to this NCI-sponsored training grant, thus equipping them to pursue successful careers in cancer research. During the previous 24 years of support, T32 CA009351 has trained an impressive group of cancer biologists who are substantially contributing to basic and translational cancer research and educational efforts at universities and research institutes throughout the United States.
Cancer is the 2nd major cause of human morbidity and mortality. Consequently, PhD and MD/PhD researchers specifically trained in the discipline of Cancer Biology and professionally involved in cancer research and educational are a critical national health need. This training grant, currently in its 25th year of continuous funding, is a cornerstone of a unique interdisciplinary graduate program designed to train the next generation of cancer biologists to meet this urgent national need.
|Murray, Andrew S; Varela, Fausto A; Hyland, Thomas E et al. (2017) Phosphorylation of the type II transmembrane serine protease, TMPRSS13, in hepatocyte growth factor activator inhibitor-1 and -2-mediated cell-surface localization. J Biol Chem 292:14867-14884|
|Blocker, Stephanie J; Douglas, Kirk A; Polin, Lisa Anne et al. (2017) Liposomal 64Cu-PET Imaging of Anti-VEGF Drug Effects on Liposomal Delivery to Colon Cancer Xenografts. Theranostics 7:4229-4239|
|Chatterjee, Madhumita; Hurley, Laura C; Tainsky, Michael A (2017) Paraneoplastic antigens as biomarkers for early diagnosis of ovarian cancer. Gynecol Oncol Rep 21:37-44|
|Watza, Donovan; Purrington, Kristen S; Chen, Kang et al. (2017) Transcriptional programs of tumor infiltrating T-cells provide insight into mechanisms of immune response and new targets for immunotherapy. J Thorac Dis 9:4162-4164|
|Sanders, Matthew A; Haynes, Brittany; Nangia-Makker, Pratima et al. (2017) Pharmacological targeting of RAD6 enzyme-mediated translesion synthesis overcomes resistance to platinum-based drugs. J Biol Chem 292:10347-10363|
|Jones, Steven K; Sarkar, Anwesha; Feldmann, Daniel P et al. (2017) Revisiting the value of competition assays in folate receptor-mediated drug delivery. Biomaterials 138:35-45|
|Haynes, Brittany; Sarma, Ashapurna; Nangia-Makker, Pratima et al. (2017) Breast cancer complexity: implications of intratumoral heterogeneity in clinical management. Cancer Metastasis Rev 36:547-555|
|Jones, Steven K; Lizzio, Vincent; Merkel, Olivia M (2016) Folate Receptor Targeted Delivery of siRNA and Paclitaxel to Ovarian Cancer Cells via Folate Conjugated Triblock Copolymer to Overcome TLR4 Driven Chemotherapy Resistance. Biomacromolecules 17:76-87|
|Najor, Nicole A; Weatherford, Layne; Brush, George S (2016) Prevention of DNA Rereplication Through a Meiotic Recombination Checkpoint Response. G3 (Bethesda) 6:3869-3881|
|Haynes, Brittany; Zhang, Yanhua; Liu, Fangchao et al. (2016) Gold nanoparticle conjugated Rad6 inhibitor induces cell death in triple negative breast cancer cells by inducing mitochondrial dysfunction and PARP-1 hyperactivation: Synthesis and characterization. Nanomedicine 12:745-757|
Showing the most recent 10 out of 143 publications